Although new treatment options are now being further evaluated in the clinic, such as targeting claudin 18.2, which is considered as a new target of advanced GC and cytotoxic T-lymphocyte antigen 4 (CTLA-4) immunotherapy (97, 98), very few of these options offer substantial survival benefits. Here, CTLA4 is linked to gastric cancer.